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TO THE EDITOR
Keratinocytes and dermal fibroblasts
express adhesive proteins that ensure
the epidermis remains attached to the
skin basement membrane and papillary
dermis. Congenital deficiency of any
of at least 15 such proteins results in a
blistering condition, termed epidermo-
lysis bullosa (EB) (Fine et al., 2008). The
most severe form of EB is the Herlitz
variant of junctional EB (JEB-H), caused
by loss-of-function mutations in one of
the three genes (LAMA3, LAMB3, and
LAMC2) encoding one of three chains
of the heterotrimeric protein laminin
332 (LM-332) (Kiritsi et al., 2011). LM-
332 is secreted by keratinocytes and
interacts with integrin receptors a3b1
and a6b4 to form focal adhesions and
stable anchoring contacts in the
dermal–epidermal junction (DEJ). Chil-
dren with this autosomal recessive
genodermatosis develop generalized
skin blistering; extensive mucosal
erosions in the upper respiratory, gas-
trointestinal, and genitourinary tracts;
infections; and, despite supportive mea-
sures, typically die within the first year
of life.
Even though it has been largely
accepted that JEB-H is untreatable
(Yuen et al., 2012), evidence from a
gene therapy trial for the less severe
(non-Herlitz) form of JEB (Mavilio et al.,
2006), and from LAMB3 gene correc-
tion of human JEB-H cells (Robbins
et al., 2001; Sakai et al., 2010), suggests
novel treatment options.
Prominent among these, the tech-
nology of reprogramming skin cells into
induced pluripotent stem cells (iPSCs),
already applied to EB (Tolar et al., 2010;
Bilousova et al., 2011; Itoh et al., 2011)
by a combination of specific transcription
factors, has the dual potential of gen-
erating patient-specific, highly prolife-
rative cells for gene-correction strate-
gies and of providing a tool for better
understanding the biology of JEB-H. We
hypothesized that such iPSCs can be
derived from JEB-H individuals. Thus,
in principle, an inexhaustible supply
of patient-specific stem cells can be
generated for local wound therapy and
for systemic administration aimed at
reaching both skin and internal mucosal
membranes.
To investigate this, we performed
skin biopsies in two individuals with
JEB-H, who carried mutations in the
LAMB3 gene: patient 1 (P1;
c.1365_1366del (p.Asn456ArgfsX7);
c.2207C4A (p.Ser736X (Varki et al.,
2006))) and patient 2 (P2; c.1903 C4T
(p.Arg635X); c.1117C4T (p.Gln373X)).
Samples were obtained with written
informed consent and following a pro-
tocol approved by the University of
Minnesota Institutional Review Board
and with adherence to the Helsinki
Guidelines. All mutations create pre-
mature stop codons in the open reading
frame, with expected nonsense-
mediated decay of the messenger RNA
or truncation of the protein product.
The children experienced extensive
areas of mucocutaneous lesions from
birth, hoarseness and stridor, numerous
infections, and progressive severe mal-
nutrition. Examination of skin sections
revealed the absence of laminin b3
chain at the DEJ. Electron microscopy
examination showed infrequent and
underdeveloped hemidesmosomes.
Collectively, these molecular, clinical,
biochemical, and ultrastructural fea-
tures were consistent with the diagnosis
of JEB-H.
To derive junctional EB–induced
pluripotent stem cells (JEB-iPSCs), we
transduced skin fibroblasts with the four
transcription factors OCT4, SOX2,
KLF4, and c-MYC, which are known
to induce pluripotency in somatic cells
(Tolar et al., 2010). Within 3 weeks of
culture, the patient-specific JEB-iPSCs
emerged as raised clusters of cells
(Figure 1a–c). To document the em-
bryonic stem cell–like cellular state, we
examined their messenger RNA and
protein expression patterns. When
compared with the parental fibroblasts,
the JEB-iPSCs expressed the genes cod-
ing for nuclear, cytoplasmic, and cell
surface proteins (e.g., TRA-1-60, TRA-
1-81, stage-specific embryonic antigens
3 and 4, Lin28, Rex1, ABCG2 and
DNMT3b, OCT4, and NANOG) in a
pattern consistent with embryonic stem
cell and iPSC phenotype (Figure 1d–m).
In support of the known activation of
endogenous expression of stem cell
genes by exogenous reprogramming
factors, the maintenance of pluripo-
tency became independent of the ori-
ginal exogenous reprogramming factors
(data not shown). As expected in fully
reprogrammed iPSCs, the epigenetic
profiles showed that endogenous
OCT4 and NANOG promoters were
largely demethylated (Supplementary
Figure S1 online). The JEB-iPSC lines
were maintained for more than 20
passages, and they showed no evidence
of genomic instability, as evidenced by
cytogenetic analysis (Supplementary
Figure S2 online). To exclude the
possibilities of cell contamination
or the mosaicism observed in JEB
(Pasmooij et al., 2007), we verified
the authenticity of the JEB-iPSCs by
genomic finger typing with competitive
PCR of a variable number of tandem
repeat polymorphisms and by seq-
uencing of LAMB3 gene mutations in
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the JEB-iPSCs (data not shown). To
show that JEB-iPSCs are capable of
differentiating into cells of endodermal,
mesodermal, and ectodermal origin,
we injected them into immune-
deficient mice lacking T cells, B cells,
and natural killer cells, and having
a macrophage defect that makes
them reliable recipients of human
cells. In 6–8 weeks, cystic teratomas
formed and cells derived from all
three embryonic layers were seen
(Figure 1n). In aggregate, these data
show that fully reprogrammed iPSCs
can be derived from skin cells of JEB-H
individuals.
JEB-iPSCs can provide means for
drug screening and to model cellular
interactions among various mucocuta-
neous cell types derived from the same
individual. To our knowledge, this is a
previously unreported use of iPSCs as
a cellular tool to study the skin
pathology in JEB. We showed first that
skin-like structures were formed in the
process of in vivo JEB-iPSC differentia-
tion (Supplementary Figure S3 online).
In contrast to wild-type iPSCs, the
skin-like structures arising from the
JEB-iPSCs expressed no detectable
laminin b3, but expressed collagen
type VII, the DEJ protein deficient
in distinct, dystrophic forms of EB
(Figure 2a–d). Next, to substantiate
the proof-of-concept that skin cell
cultures can be derived from JEB-
iPSCs, we differentiated JEB-iPSCs into
keratinocytes (Supplementary Figures
S4 and S5 online). Lastly, to demon-
strate that this operating procedure
can serve as a platform for gene
correction of these highly proliferative
cells, we transduced the JEB-iPSCs with
LAMB3 gene. After transduction, the
JEB-iPSC–derived cells expressed and
secreted LM-332 heterotrimeric protein
(Figure 2e).
In summary, we have shown that the
LAMB3 defect does not preclude repro-
gramming into pluripotency, as has
been observed in other genetic diseases
(Raya et al., 2009). We have also
shown that the JEB-iPSCs—in addition
to establishing a reliable stem cell
source for gene therapy interventions
in JEB-H—can be used in the study of
early human skin formation and com-
pared with LM-332 in early develop-
ment. With the ultimate clinical
application of iPSC technology in mind,
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Figure 1. Expression profile of junctional epidermolysis bullosa–induced pluripotent stem cells (JEB-iPSCs). (a–l) To assess the ability of expressing embryonic
stem cell proteins, JEB-iPSCs were live stained with TRA-1-60, viewed in phase contrast (PC), and immunostained with TRA-1-81, SSEA3, SSEA4, OCT4, TRA-1-
60, and NANOG. Corresponding images stained with 4,6-diamidino-2-phenylindole (DAPI) show the nuclei of individual cells in the colonies. Bar¼100 mm.
(m) Quantitative reverse transcription PCR analysis of OCT4, SOX2, NANOG, KLF4, c-MYC, LIN28, REX01, ABCG2, and DNMT3b in parental Herlitz variant
of junctional EB (JEB-H) fibroblasts (FB, red bars) and three independent JEB-H iPSC lines (iPSC clones 1, 2, and 3 denoted with green, blue, and violet bars,
respectively). All values were normalized against endogenous glyceraldehyde-3-phosphate dehydrogenase expression. (n) JEB-H iPSC–derived teratoma
differentiated into cells of all three germ lines. The same histological section of mature teratoma from an immunodeficient mouse shows melanocytes of
ectodermal origin, cartilage of mesodermal origin, and columnar epithelium with goblet cells of endodermal origin (hematoxylin–eosin). The findings
were analogous for both P1 and P2; therefore, data for P1 are shown here as a representative example. Detailed methods are included as Supplementary
Information online. AP, alkaline phosphatase.
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iPSCs from JEB cells
it is worth noting that strategies exist
for genome-nonintegrating reprogram-
ming, for depletion of tumor-inducing
cells from differentiated iPSC cultures,
and—as a JEB-H individual can
develop anti-LM-332 antibody—for
induction of immunological tolerance
to disease-correcting transgenes (Vailly
et al., 1998; Wu and Hochedlinger,
2011). Thus, gene-corrected JEB-iPSCs
can inform medical advances in this
severe and lethal blistering disease,
as well as in additional extracellular
matrix disorders of the skin and other
tissues (McGowan and Marinkovich,
2000).
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TO THE EDITOR
Rotating night-shift work causes
chronic circadian misalignment be-
tween the endogenous circadian timing
system and behavioral cycles and sup-
presses the secretion of melatonin
(James et al., 2007; Scheer et al.,
2009). Melatonin has been found to
regulate the inflammatory response and
have antioxidant effects (Bonnefont-
Rousselot and Collin, 2010; Ochoa
et al., 2011), which may thereby
protect against psoriasis. One prior
study showed that psoriatics had
reduced plasma melatonin (Mozzanica
et al., 1988). A growing body of
literature provides evidence linking
night-shift work with various health
conditions, including psoriasis comor-
bidities such as coronary heart disease
and type 2 diabetes (Kawachi et al.,
1995; Gelfand et al., 2006; Pan et al.,
2011; Li et al., 2012b). However, no
direct evidence of an association be-
tween night-shift work and psoriasis is
available. Here, we evaluated the
association between rotating night-shift
work and incident risk of psoriasis in
two large, prospective cohort studies,
the Nurses’ Health study (NHS)
(1988–2008) and NHS II (1989–2005).
Details on the cohorts and ascertain-
ment of psoriasis have been described
previously (Li et al., 2012b). Participants
responded to clinician-diagnosed psoria-
sis in the 2008 (NHS) or 2005 (NHS II)
questionnaires with high validity. Partici-
pants were asked about lifetime years
working in rotating night shifts in the
1988 (NHS) and 1989 (NHS II) ques-
tionnaires. We classified participants into
two major categories: never or ever
working in rotating night shifts. The
participants were further categorized by
the duration of shift work: 1–2, 3–9, or
X10 years. Information on covariates
was collected from the questionnaires
biennially. From the responders to the
follow-up beginning and ending ques-
tionnaires, we excluded psoriasis preva-
lent cases, unknown diagnosis date, and
unknown status of night-shift work:
62,487 in NHS and 95,561 in NHS II
remained in the analysis.
We calculated person-years of fol-
low-up for each participant from the
return date of 1988 (NHS) or 1989
(NHS II) questionnaire to the date of
diagnosis of psoriasis, or the end of
follow-up (June 2008 for NHS and June
2005 for NHS II), whichever came first.
Time-dependent Cox proportional ha-
zards models adjusting for 2-year time
intervals were used to estimate the
hazard ratios (HRs) and 95% confi-
dence interval (CI) of developing psor-
iasis in night-shift workers, adjusting for
age, body mass index (BMI), smoking,
alcohol intake, and physical activity.
The time-varying covariates were up-
dated in the analysis. For the combined
analysis, we tested the between-studies
heterogeneity and estimated the overall
association using meta-analysis. The
institutional review board of Brigham
and Women’s Hospital approved this
study.
In NHS, 58.8% reported ever work-
ing in rotating night shifts for at least
1 year, with 10.9% reportingX10 years
of rotating night-shift work. In NHS II,
61.6% reported ever working in rotat-
ing night shifts, with 4.5% working for
X10 years. In both cohorts, those ever
working in rotating night shifts tended
to have a higher BMI and were more
likely to be physically active or current
smokers (Table 1). Overall, 1,887 in-
cident psoriasis cases were identified
during follow-up. Compared with those
who reported no night-shift work, those
ever working in rotating night shifts at
baseline had a significantly increased
risk of psoriasis. The multivariate-
adjusted HR (95% CI) was 1.26
(1.09–1.47) in NHS, 1.14 (1.01–1.28)
in NHS II, and 1.19 (1.07–1.32) in
combined cohorts. We evaluated the
risk of psoriasis by duration of rotating
night-shift work, and the multivariate-
adjusted HRs (95% CIs) in the com-
bined cohorts were 1.20 (1.07–1.34),
1.17 (1.00–1.38), and 1.23 (1.03–1.47)
for 1–2, 3–9, and X10 years of working
in rotating night shifts, respectively
(Table 2). Further adjustments by parity,
postmenopausal hormone use, depres-
sion, personal history of psoriasisAbbreviations: BMI, body mass index; CI, confidence interval; NHS II, Nurses’ Health Study II
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